UNSPSC 51202004: Tolvaptan

This classification denotes a vasopressin antagonist with the molecular formula C26H25ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21G72T1950, chemically known as 7-chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1h-1-benzazepine but generally known as tolvaptan, which bears US NIH Compound Identifier 216237. European Medicines Agency schedules Tolvaptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22755.

UNSPSC 51202004 Tolvaptan, a Commodity code, shows minimal relevant recent state and local activity aligned with its nominal pharmaceutical scope. The single recent opportunity posted under this code — a Mississippi State Department of Health sole source notice for Yellow Fever Vaccine from Sanofi Pasteur, Inc., due August 3, 2026 — involves a vaccine product and procurement mechanism entirely misaligned with the Tolvaptan code classification. Tolvaptan is a hypertonic solution used in clinical settings for treatment of hyponatremia, while the Mississippi opportunity concerns immunization procurement through a sole source objection process. The mismatch suggests either an administrative coding error in the solicitation or that this Commodity code does not currently reflect active state and local purchasing patterns in its intended product category.

No substantive recent opportunities are present in the source that genuinely procure tolvaptan or pharmaceutical products aligned with the code's definition. The single listing does not support characterization of issuing-body concentration, geographic activity, or representative procurement patterns under the code. Firms evaluating this Commodity code should monitor for future activity but recognize that current state and local contracting visibility under 51202004 does not extend to tolvaptan procurement.